NCT00441883 - Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma | Biotech Hunter

Enrollment

176

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

July 31, 2008

Conditions

Primary Open Angle GlaucomaOcular HypertensionPigmentary GlaucomaPseudoexfoliative Glaucoma

Interventions

DRUG

PF-03187207 and Latanoprost Vehicle

DRUG

Latanoprost 0.005% and PF-03187207 Vehicle

Trial Locations (19)

14618

Pfizer Investigational Site, Rochester

15238

Pfizer Investigational Site, Pittsburgh

16066

Pfizer Investigational Site, Cranberry Township

27262

Pfizer Investigational Site, High Point

28210

Pfizer Investigational Site, Charlotte

30339

Pfizer Investigational Site, Atlanta

30342

Pfizer Investigational Site, Atlanta

32174

Pfizer Investigational Site, Ormond Beach

32204

Pfizer Investigational Site, Jacksonville

38119

Pfizer Investigational Site, Memphis

40217

Pfizer Investigational Site, Louisville

47710

Pfizer Investigational Site, Evansville

74104

Pfizer Investigational Site, Tulsa

78705

Pfizer Investigational Site, Austin

90701

Pfizer Investigational Site, Artesia

92064

Pfizer Investigational Site, Poway

92663

Pfizer Investigational Site, Newport Beach

94954

Pfizer Investigational Site, Petaluma

06810-4004

Pfizer Investigational Site, Danbury

All Listed Sponsors

collaborator

NicOx Inc.

INDUSTRY

lead

Bausch & Lomb Incorporated

INDUSTRY